合成致死性：以癌抗癌。 - Suppr

Suppr

超能文献

Synthetic lethality: killing cancer with cancer.

作者信息

Garber Ken

出版信息

J Natl Cancer Inst. 2002 Nov 20;94(22):1666-8. doi: 10.1093/jnci/94.22.1666.

DOI:10.1093/jnci/94.22.1666

PMID:12441317

Abstract

摘要

相似文献

Synthetic lethality: killing cancer with cancer.

J Natl Cancer Inst. 2002 Nov 20;94(22):1666-8. doi: 10.1093/jnci/94.22.1666.

Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.

Clin Cancer Res. 2005 Aug 1;11(15):5631-8. doi: 10.1158/1078-0432.CCR-05-0398.

Imatinib: paradigm or anomaly?

Cell Cycle. 2004 Jul;3(7):833-5. Epub 2004 Jul 8.

[Heat shock protein 90: novel target for cancer therapy].

Ai Zheng. 2004 Aug;23(8):968-74.

Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2239-47. doi: 10.1158/1078-0432.CCR-05-2282.

Scientists hopeful as they uncover molecular clues to prostate cancer.

J Natl Cancer Inst. 2005 Feb 2;97(3):168-9. doi: 10.1093/jnci/97.3.168.

Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.

Mol Pharmacol. 2005 Apr;67(4):1166-76. doi: 10.1124/mol.104.007831. Epub 2004 Dec 29.

Cancer: the rules of attraction.

Nature. 2003 Sep 25;425(6956):357-9. doi: 10.1038/425357a.

Heat shock protein inhibitor shows antitumor activity.

J Natl Cancer Inst. 2002 Aug 21;94(16):1194-5. doi: 10.1093/jnci/94.16.1194.

The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.

Clin Cancer Res. 2011 Sep 1;17(17):5604-14. doi: 10.1158/1078-0432.CCR-11-0562. Epub 2011 Jul 7.

引用本文的文献

A Phase II Multicenter Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma.

Clin Cancer Res. 2025 Jul 15;31(14):2919-2925. doi: 10.1158/1078-0432.CCR-25-0298.

Molecularly targeted therapies for p53-mutant cancers.

Cell Mol Life Sci. 2017 Nov;74(22):4171-4187. doi: 10.1007/s00018-017-2575-0. Epub 2017 Jun 22.

Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.

Oncotarget. 2017 Apr 25;8(17):28971-28989. doi: 10.18632/oncotarget.15952.

Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines.

J Breast Cancer. 2015 Dec;18(4):329-38. doi: 10.4048/jbc.2015.18.4.329. Epub 2015 Dec 23.

Towards a compendium of essential genes - From model organisms to synthetic lethality in cancer cells.

Crit Rev Biochem Mol Biol. 2016;51(2):74-85. doi: 10.3109/10409238.2015.1117053. Epub 2015 Dec 1.

Therapeutic targets in melanoma: map kinase pathway.

Curr Oncol Rep. 2006 Sep;8(5):400-5. doi: 10.1007/s11912-006-0065-x.

TOR controls transcriptional and translational programs via Sap-Sit4 protein phosphatase signaling effectors.

Mol Cell Biol. 2004 Oct;24(19):8332-41. doi: 10.1128/MCB.24.19.8332-8341.2004.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验